Astellas Pharma Inc

Explore how Astellas’ new GI oncology data and market strategy can drive growth in gastric cancer treatment and broader therapeutic segments.

Discover how Astellas Pharma’s precision‑medicine pipeline—targeting ovarian cancer, chordoma, GI oncology and more—drives global growth, market expansion and innovative partnerships.

Explore Astellas Pharma’s Q2 2026 & FY 2025 earnings transcripts—see how its urology, oncology, immunology and metabolic therapies drive growth, R&D investment, and strategic roadmap.

Astellas Pharma Inc. has announced positive results from a Phase IV clinical trial of fezolinetant for menopausal symptoms and received FDA priority review for PADCEV in muscle-invasive bladder cancer, driving an upward trend in the company’s share …

Astellas Pharma Inc. has reported positive clinical trial results and strategic advancements in its therapeutic areas, positioning the company for long-term success in the pharmaceutical market.

Astellas Pharma Inc. is navigating a complex market landscape, with opportunities for growth in China’s evolving intellectual property landscape and the emerging TROP2-targeted antibody-drug conjugate market, but faces challenges in innovation, geog…

Astellas Pharma Inc’s market position is stable, with growth prospects driven by its focus on oncology and related therapeutic areas, particularly in androgen receptor-targeted therapies.

Astellas Pharma has reported significant profit growth in the first quarter, driven by research and development efforts, product portfolio expansion, and growing demand for cell therapy treatments.

Astellas Pharma’s stock price has surged significantly due to the company’s growing appeal to investors and its strong focus on oncology and targeted therapies.

Astellas Pharma has partnered with the Korea Institute of Startup and Entrepreneurship Development to give Korean drug-discovery startups access to its cutting-edge research facilities and expertise.